Risen Pharmaceutical Technology

Risen Pharmaceutical Technology (Risen Pharma) is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to developing innovative therapeutics for degenerative diseases, oncology, and metabolic disorders. The company utilizes a multi-modality approach, leveraging proprietary platforms in small molecules, PROTACs, and siRNA to address significant unmet medical needs. Risen's lead candidate, RP903, is a selective PI3Kα inhibitor currently in Phase 3 clinical trials for PIK3CA-mutant breast cancer. Other key programs include RP901, a potential first-in-class oral therapy for osteoarthritis in Phase 2, and RP902, a deuterated small molecule for Alzheimer's disease. With R&D centers in Shanghai and Suzhou and a large-scale manufacturing facility in Lingang, Risen is positioned to manage the full lifecycle of drug development from discovery to commercialization.